/PRNewswire/ Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, and Medison Pharma, a.
/PRNewswire/ Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, and Medison Pharma, a.
/PRNewswire/ Hansa Biopharma AB (Nasdaq Stockholm: HNSA) will publish its interim report for January-September 2021 at 8:00 CET on October 21, 2021. All.
Hansa Biopharma presented new data on imlifidase at the European Society for Organ Transplantation (ESOT) Congress prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.